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Helicobacter pylori are gram negative spiral bacteria that colonize the human stomach. Infection with H. 
pylori is associated with chronic gastritis, peptic ulcer, gastric adenocarcinoma and gastric mucosa-
associated lymphoid tissue (MALT) lymphoma. Antibiotic resistance is an ever increasing problem with 
the treatment of most microbial infections including H. pylori; and has become a growing problem 
worldwide with the eradication of this organism. In recent years, several treatment regimens have been 
proposed for H. pylori eradication. However, the only conditions for which such treatment is strongly 
recommended on the basis of unequivocal supporting evidence are peptic ulcer disease and low grade 
gastric MALT lymphoma. Success of antimicrobial regimens for H. pylori eradication depends on 
patient compliance and lack of antimicrobial resistance. Metronidazole (Mtz) containing regimens have 
been shown to limit effectiveness because of increasing prevalence of resistance to this drug.  A high 
prevalence (> 90%) of Mtz resistance in H. pylori has been reported especially in developing countries. 
Mtz resistance may be mediated through an inability of Mtz-resistant strains to remove oxygen from the 
site of Mtz reduction, thereby preventing Mtz activation.  This has been attributed to a mutation on the 
frxA and/or rdxA genes resulting in strains of the organism with defective nitro-reductases coded by 
these genes. Infection by Mtz or amoxicillin resistant strains is an important factor leading to treatment 
failure; subjecting all H. pylori clinical isolates to susceptibility testing most especially to Mtz is 
recommended. If not possible, a program to survey the prevalence of resistance should be 
implemented in a given area or population. This increasing emergence of antimicrobial resistance in H. 
pylori treatment posses serious public health problems and is therefore necessary that new drug 
regimens be examined.  
 





Helicobacter pylori are gram negative spiral bacteria that 
colonize the human stomach. Infection with the organism 
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adenocarcinoma and gastric MALT lymphoma (Suerbaum 
and Michetti, 2002; Ndip et al., 2004, 2008). Simple 
blood, breath and stool tests can determine if one is infected 
with H. pylori. The most accurate way to diagnose H. 
pylori, however, is through upper endoscopy of the oeso-
phagus, stomach and duodenum (Ables et al., 2007). 
Eradication of the organism has been shown to result in 
ulcer healing, prevention of peptic ulcer recurrence and 
may also reduce the prevalence of gastric cancer in high 
risk populations (Sepulvedo and Coelho, 2002; Tanih et 
al., 2009). 
Antibiotic resistance is an ever increasing problem  with  




the treatment of most microbial infections including H. 
pylori infection (Hoffman, 1999; Thyagarajan et al., 2003). 
New antimicrobial agents are therefore being developed 
to overcome the problem of antibiotic resistance in bacterial 
pathogens, such as combination of antibiotics with plant 
extract and other natural products that possess anti-
microbial activity (Chaudhuri et al., 2003; Ndip et al., 
2007a,b; Tanih et al., 2009). Combinations of drugs have 
often been used for the treatment of drug resistant 
infections as this takes advantage of different mechanisms 
of action (Chaudhuri et al., 2003). 
Antibiotic resistance with regard to H. pylori eradication 
has become a growing problem both in the developing 
and in developed countries. Mtz was initially used against 
a diversity of anaerobic microorganisms but was later 
established to have activity against certain microaerophilic 
organisms such as H. pylori. At present, Mtz is a corner-
stone of many triple-therapy formulations for the eradi-
cation of H. pylori. However, resistance approaches 90% 
in many developing countries and even in Western 
Europe it ranges from 5 to 50% (Alarcon et al., 1999). In 
some countries, the prevalence of Mtz resistant strains 
approaches 70-100% and is associated with prior 
exposure to the drug (Noach et al., 1994; Goddard and 
Logan, 1996; Ndip et al., 2008). While several triple and 
quadruple-therapy formulations use more than one 
antibiotic, Mtz resistance has a profound effect on the 
efficacy of these regimens (van der Wouden et al., 1997, 
2000, 2001). 
Based on findings of several studies, the currently 
recommended therapy for the eradication of H. pylori 
infection include proton pump inhibitors (PPIs) such as 
omeprazole, lanoprazole, rabeprazole, or pantoprazole 
together with clarithromycin and either Mtz or amoxicillin 
(Salcedo and Al-Kawas, 1998; Veldhuyzen et al., 1998; 
Chaudhuri et al., 2003; Ndip et al., 2008). Success rates 
of cure with the use of these combination therapy ranges 
from 85 to 95%. However resistance to Mtz or clarithro-
mycin results in an increased failure rate of therapies 
(Megraud, 1997). The emerging resistance to Mtz limits 
its use in the treatment of infections; and this problem is 
encountered more in Africa (Asrat et al., 2004; Ndip et al., 
2008; Tanih et al., 2009). The resistance mechanisms in 
anaerobic organisms and H. pylori vary. Mtz, a synthetic 
nitroimidazole (Figure 1), is a prodrug and becomes 
active when reduced in the cytosol of the microorganism 
to a toxic metabolite. Unstable Mtz radicals react rapidly 
with proteins, RNA and DNA, eventually resulting in cell 
death. Under the conditions of low-redox potential in 
anaerobic organisms, drug activation can be catalyzed by 
nitroreductases such as pyruvateflavodoxin reductase by 
means of a single electron transfer event. H. pylori 
possesses this enzyme, but owing to its microaerophilic 
nature, molecular oxygen is also present and can compete 
with the Mtz radical for electrons in a futile cycle that 
restores the prodrug along with super oxide. Instead, a 
separate mechanism seems to account for most Mtz 












oxygen-sensitive NADPH nitroreductase encoded by the 
rdxA gene reduces Mtz by a two-electron transfer step 
into a toxic metabolite that cannot be retransformed to its 
parent by molecular oxygen. The vast majority of 
clinically isolated (Tankovic et al., 2000) or experimentally 
induced (Jenks et al., 1999) Mtz-resistant clones contain 
a mutation somewhere in the rdxA coding sequence. 
However, there have been reports that mutation of a 
second reductase NAD(P)H-flavin oxidoreductase 
encoded by frxA could also confer low-level Mtz 
sensitivity in some strains (Kwon et al., 2001) and a role 
for oxygen sensitive reductases has not been formally 
excluded. Sequencing candidate genes, such as the 
reductases (mentioned above), in sensitive and resistant 
isolates has provided support for the idea of these genes 
playing a role in resistance, but reports also show that 
frameshift mutations in frxA occur with similar frequencies 
in sensitive and resistant strains (Chisholm and Owen, 
2004). Jeong et al. (2000), concluded that most Mtz 
resistance in H. pylori depend on rdxA inactivation, of 
which mutations in frxA can enhance resistance, and that 
genes conferring Mtz resistance without rdxA inactivation 
are rare or nonexistent in H. pylori populations. Although 
null mutations in a rdxA gene that encodes oxygen-
insensitive NAD(P)H nitroreductase was reported in Mtz-
resistant H. pylori, an intact rdxA gene has also been 
reported in Mtz-resistant H. pylori, suggesting that addi-
tional Mtz resistance mechanisms exist in H. pylori (Kwon 
et al., 2000a). In this paper, we present an overview of 
Mtz resistance as well as the roles of the putative genes 
frxA and frxA implicated in Mtz resistance. 
 
 
TREATMENT OF H. PYLORI INFECTION  
 
In recent years, several treatment regimens have been 
proposed for the eradication of H pylori. However, the 
only conditions for which such treatment is strongly 
recommended on the basis of unequivocal supporting 
evidence are peptic ulcer disease and low grade gastric 
MALT lymphoma (Graham, 1998). Success of anti-
microbial regimens for H. pylori eradication depends on 
patient compliance and lack of antimicrobial resistance. 
Thus, complicated regimens or those associated with side 





to eradicate the organism (Lesbros-Pantoflickova et al., 
2007; Ndip et al., 2008). Theoretically, therapies have 
improved such that regimens should demonstrate 85 to 
95% efficacy. Single-agent therapy should not be used 
because of the unacceptably low eradication rates. 
Clinical trials have shown that multidrug regimens (triple 
therapy) are the most effective treatment with eradication 
rates of up to 96% (Lamouliatte et al., 1996; Salcedo and 
Al-Kawas, 1998; Kwon et al., 2001; Aboderin et al., 
2007). Despite these high eradication rates, the problem 
of drug resistance is still well established. The regimen of 
choice is a PPI or ranitidine bismuth citrate (Tritec) plus 
two antibiotics for 14 days (Megraud and Lehours, 2007; 
Ndip et al., 2008). Mtz, clarithromycin, amoxicillin and 
tetracycline are the major antibiotics prescribed for H. 
pylori eradication (Goddard et al., 1996; Kobayashi et al., 
2001; Megraud, 2004).  These agents have superior 
efficacy to and are better tolerated than the standard 
bismuth based triple therapy consisting of bismuth 
subsalicylate, metronidazole (flagyl) and tetracycline 






Mtz is a nitroimidazole used principally for the treatment 
of anaerobic and parasitic infections. Mtz is stable at a 
low pH and is actively secreted into the gastric juice 
(Edwards, 1993). Active secretion of Mtz is reduced when 
it is given with a proton pump inhibitor (Goddard et al., 
1996) and has been reported to have a half-life of 8 to 12 
h. The most common adverse effects of Mtz are a metallic 
taste in the oral cavity, nausea and epigastric discomfort. 
Mtz has been reported to produce a disulfiram like 
reaction when taken in combination with alcohol. In the 
past two decades, Mtz has become a stronghold in the 
treatment of H. pylori infection. In Western countries 
where Mtz use is very minimal, more than 70% of H. 
pylori isolates are sensitive to it (Glupczynski, 1992); 
however, more recent data has indicated an Mtz resis-
tance of 10-50% of all adult patients infected with H. 
pylori in the developed world (Lopez-Brea et al., 1997; 
Osato et al., 1999; Adamek et al., 1998). In fact, in 
developing countries where Mtz use is more common, 
there have been reports that more than 80% of H. pylori 
isolates are Mtz resistant (Bell et al., 1992; Tanih et al., 
2010). H. pylori eradication is rarely achieved when it is 
administered as a single agent. Therefore, Mtz is always 
given in combination with one or more antibiotics, that is, 
multiple therapies (Chowdhurger et al., 2002). Mtz 
resistance may be mediated through an inability of Mtz -
resistant strains to remove oxygen from the site of Mtz 
reduction, thereby preventing Mtz activation. This has 
been attributed to a mutation on the frxA and/or rdxA 
genes resulting in a strain of H. pylori with defective nitro-
reductases coded by these genes (Cederbrant et al., 
1992; Kwon et al., 2000a; Paul et al., 2001).  Resistance  




is defined by a cut off value, which depends on the 
minimum inhibitory concentration (MIC) of the strains and 
on the concentration of antibiotic that can be achieved in 
the tissue by a given therapeutic dose (Megraud and 
Doermann, 1998; Thyagarajan et al., 2003).  Although 
the Clinical Laboratory Standard Institute (CLSI) has not 
designated a MIC breakpoint for Mtz, values of  8 µg/ml 
have been proposed (Vasques et al., 1996; Osato, 2000; 
CLSI, 2007). In a recent study in the Eastern Cape 
Province of South Africa, we reported a MIC value of > 10 
µg/ml for Mtz (Tanih et al., 2010). 
 
 
TRENDS IN METRONIDAZOLE RESISTANCE 
 
A systematic review of the data on antibiotic resistance 
published in the last 5 years highlighted regional diffe-
rences in resistance pattern for Mtz and clarithromycin 
(Megraud, 2004). Mtz containing regimens have been 
shown to limit effectiveness because of increasing 
prevalence of resistance to this drug (Ching et al., 1996; 
Wang et al., 2000; Al-Quarashi et al., 2001). In a study in 
Egypt, a universal high-level primary Mtz resistance in 
children, compared to lower resistances to other selected 
antibiotic was reported by Sherif et al. (2004), which  is 
consistent with other reports in Africa (Wang et al., 2000; 
Al-Quarashi et al., 2001; Ndip et al., 2008; Tanih et al., 
2009). Very high resistances to Mtz and amoxicillin have 
been reported in Nigerian, Kenyan and Cameroonian 
patients (Abdulrashed et al., 2005; Lwai-lume et al., 
2005; Aboderin et al., 2007; Ndip et al., 2008). Eradi-
cation failures in children are mostly due to non compliance 
because of adverse effects or due to resistance to Mtz 
and clarithromycin. In Cameroon, Ndip et al. (2008) 
revealed a very high antimicrobial resistance rate of 93.2% 
for Mtz. A similar study in Western Nigeria documented 
100% resistance of H. pylori strains to Mtz (Smith et al., 
2001). Equally, in a study conducted in Ethiopia, Asrat et 
al. (2004) found 76% of their strains resistant to Mtz. 
Mtz containing regimens have been shown to limit 
effectiveness because of increasing prevalence of 
resistance to this drug (Wang et al., 2000; Al-Quarashi et 
al., 2001; Abdul et al., 2001). Patients originating from 
Africa have been reported to harbour resistant strains 
significantly more than those from other parts of the world 
(Megraud, 2004). Resistance rates as high as 75 - 98% 
have been reported in some areas of South Africa (Wong 
et al., 2000; Tanih et al., 2010) and up to 100% in 
Ethiopia. The problem of Mtz resistance was thought to 
be ameliorated when the drug was used in combination 
with clarithromycin (Hardin and Wright, 2002). However, 
high resistance to clarithromycin has been reported in 
patients originating from Africa (Loffeld et al. 2003).  
Banatvala et al. (1994) in their study documented that 
women born in the United Kingdom, were more likely to 
harbour Mtz-resistant H. pylori strains than men (54 v 
18% respectively) and more likely to have a history of 
previous nitroimidazole ingestion (41 v 11% respectively);  




and patients previously exposed to either Mtz or tini-
dazole were more likely to harbour resistant strains (84 v 
41%). 
 Mtz consumption appears to be an important risk 
factor for this resistance. A marked difference has been 
found between the rate of resistance to nitroimidazoles in 
developed and developing countries. This difference may 
be linked to the high level of general use of the drug in 
developing countries to treat parasitic infections such as 
amoebiasis (Alarcon et al., 1999) because it is inexpensive 
and also commonly sold in the street corners heralding 
untold resistances to it. The cause of this resistance may 
also be linked to the use of these compounds for genital 
infections, especially trichomonasis  and therefore, strains 
isolated from women are more likely to be resistant than 
strains isolated from men (Banatvala et al., 1994; Alarcon 
et al., 1999; Cameron et al., 2004; Ndip et al., 2008). 
Another possible cause may be the use of these com-
pounds to treat dental infections (Megraud, 1997).  
Studies of H. pylori antibiotic resistance in South Africa 
are lacking. This could be a serious problem owing to the 
fact that susceptibility patterns are changing globally, and 
rapidly too. As a result, eradication failures will be 
frequent as some of the drugs given to the patients may 
fail to produce the desired effects and yet left on the shelf.  
However, we reported an Mtz-resistance of 95.5% in a 
recent study we conducted in South Africa (Tanih et al., 
2010) which seems to corroborate earlier reports made in 
other African countries, thus, confirming high Mtz-resis-
tance in the developing world.  
 
 
THE ROLE OF RdxA NITROREDUCTASE IN 
METRONIDAZOLE RESISTANCE 
 
The elemental discovery two decades ago by Goodwin et 
al. (1998) that H. pylori Mtz resistance may be a result of 
loss of activity of an oxygen independent NADPH nitro-
reductase encoded by the gene rdxA marked the esta-
blishment of a renewed and intense interest in gaining a 
full understanding of the causes of resistance to this 
drug. Mutational inactivation of rdxA was initially pro-
posed as the cause of naturally acquired Mtz resistance 
in H. pylori (Goodwin et al., 1998), and various features 
of rdxA, such as the polypeptide it encodes, were sug-
gested as the molecular bases for a low redox potential 
capable of reducing Mtz (Kwon et al., 2000b). However, 
the results of further studies to verify this hypothesis 
revealed other enzyme activities with biological functions 
different from nitroreductases that appear to modulate 
Mtz reduction and were thus proposed as potential candi-
dates to cause resistance to this drug in H. pylori (Jeong 
et al., 2001). As a follow up to these data, successive 
modifications were proposed to the initial hypothesis, with 
the result that the association of rdxA in susceptibility to 
Mtz is accepted currently, but its specific role is unclear to 





on the involvement of rdxA nitroreductase in the Mtz sen-
sitive (MtzS) phenotype of H. pylori and the specification 
of rdxA inactivation as the necessary and sufficient cause 
of Mtz resistance in this bacterium, were proposed by 
Goodwin et al. (1998). 
Goodwin et al. (1998) demonstrated that intrinsically 
resistant E. coli transformed with functional H. pylori rdxA 
became sensitive to Mtz, and assays of the reduction of 
the drug by one of the clones demonstrated the func-
tionality of the protein expressed in E. coli. The study 
showed that introduction of rdxA into Mtz resistant (MtzR) 
H. pylori rendered them MtzS, that isogenic rdxA knockout 
H. pylori mutants of an MtzS parent became MtzR and that 
rdxA genes originating from matched pairs of MtzS and 
MtzR strains differed from one another by several base 
substitutions (Goodwin et al., 1998). It was also demon-
strated that in rdxA alleles that showed extensive 
deletions, insertions of transposable elements (Debets-
Ossenkopp, 1999; Tankovic et al., 2000; Kwon et al., 
2000b) or mutations leading to stop codons which could 
result in premature translation, termination and truncated 
polypeptides (Jenks et al., 1999; Tankovic et al., 2000), 
would lead to a situation whereby the corresponding rdxA 
will not be expressed or functional. Several studies have 
also demonstrated the large heterogeneity of point muta-
tions present in the rdxA genes of resistant strains, with 
no particular nucleotide mutation or amino acid substi-
tution that could be linked to Mtz resistance with the 
exception of mutations generating stop signals (Goodwin 
et al., 1998; Debets-Ossenkopp, 1999; Jenks et al., 1999; 
Tankovic et al., 2000; Kwon et al., 2000a; Solca et al., 
2000; Jeong et al., 2000; Kwon et al., 2001; Paul et al., 
2001; Jorgensen et al., 2001). Other studies have also 
revealed the existence of unchanged rdxA in sensitive 
and resistant isolates and of different rdxA in MtzS strains 
(Jenks et al., 1999; Tankovic et al., 2000). In contrast 
with resistance mechanisms for other antibiotics, the 
resistance mechanism of Mtz is complex (Mendz and 
Megraud, 2002; Chisholm and Owen, 2003). Clearly, 
alterations of the rdxA gene are of prime importance but it 
has not been possible to identify a clear panel of point 
mutations which could explain the phenomenon. Moreover, 
research data still question the unequivocal linkage 
between rdxA mutations and the resistant phenotype. 
Additionally, other genes such as frxA also seem to be 
involved (Marais et al., 2003). 
 
 
THE ROLE OF FrxA NITROREDUCTASE IN 
METRONIDAZOLE RESISTANCE 
 
Studies of the role in resistance of other enzymes poten-
tially capable of reducing Mtz have yielded mixed results 
(Hoffman et al., 1996; Kaihovaara et al., 1998; Kwon et 
al., 2000b). The discovery of frameshift mutations in the 
gene frxA, encoding an NAD (P) H: flavin oxidoreductase, 





H. pylori (Kwon et al., 2000b). 
In a study by Kwon et al. (2000b), confirmation was 
obtained by transforming MtzS strains with the mutated 
frxA, and by inactivation of this gene in sensitive strains. 
Furthermore, an E. coli resistant strain transformed with 
the frxA gene of an H. pylori MtzS strain was capable of 
reducing Mtz, and was rendered sensitive to the drug. 
Several studies have demonstrated that inactivation of 
rdxA or frxA led to increase in the MIC for Mtz and 
simultaneous inactivation of both genes led to higher MIC 
than the inactivation of either gene (Kwon et al., 2000a), 
thus providing a possible explanation for the hetero-
geneity of resistance observed in the wide range of MIC 
for Mtz measured in H. pylori strains. These findings have 
motivated several studies designed to verify the role of 
frxA in Mtz resistance and a synergy of the interpretations 
of the data obtained for frxA and rdxA, revisiting  the 
methods used in the studies of rdxA (Jeong and Berg, 
2000; Kwon et al., 2001; Jeong et al., 2000, 2001). 
Interestingly, there is general agreement that both rdxA 
and frxA have roles in Mtz resistance, but there are some 
differences in two important points:  
The roles of frxA and rdxA in Mtz resistance, and their 
relative contributions to the MIC for Mtz. In one analysis, 
deficiencies in either rdxA, frxA or both explained the 
resistant phenotype, even though with mutations in frxA 
alone yielding low-level Mtz resistance in clinical isolates, 
and moderate-to-high-level Mtz resistance in laboratory 
mutants with a disrupted gene (Jeong et al., 2000). 
In contrary to this, it has been observed that H. pylori 
strains become resistant to Mtz in two ways: by inacti-
vation of rdxA (type I) or by inactivation of both rdxA and 
frxA (type II), and rarely, if ever by inactivation of frxA 
alone, disruption of rdxA alone can produce Mtz resis-
tance at all levels, and mutations in frxA can enhance the 
level of resistance of type I strains (Jeong et al., 2000; 
Jeong and Berg, 2000; Jeong et al., 2001). In spite of the 
common argument shared by both views, there are 
significant differences in the data and their 
interpretations; it has not been possible to identify a clear 
panel of mutations which could explain the phenomenon 





Infection by Mtz or amoxicillin resistant strains is an 
important factor leading to treatment failure; subjecting all 
H. pylori clinical isolates to susceptibility testing most 
especially to Mtz is recommended (Megraud, 2004). If not 
possible, a program to survey the prevalence of resis-
tance should be implemented in a given area or population. 
This increasing emergence of antimicrobial resistance in 
H. pylori treatment posses serious public health problems 
and is therefore necessary that new drug regimens be 
examined. Studies are currently underway in our group to 
study the role of Mtz in the  treatment  of  H. pylori  in  our  




environment (Tanih et al., 2010). We have already deter-
mined the prevalence of Mtz resistance and successfully 
amplified the two putative resistance genes (rfxA and 
frxA) implicated in Mtz resistance. Sequencing of these 
genes, which is our next line of experiments, is expected 
to add to existing global knowledge the types of 
mutations involved and consequently the roles of these 
genes in Mtz resistance in H. pylori strains circulating in 
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